crashtestdummy
Platinum Member
- Feb 18, 2010
- 2,893
- 0
- 0
Some scientist might want to find a cure, but the executives who control everything don't, they want the opposite more sick people, would be surprised if secretly some HIV drugs are designed with a hidden function to make HIV spread more easily. Or cancer drugs that make sure some people have relapses or never experience full remission. These companies want people sick
You really don't understand how markets work, do you? Rather than re-write everything, this is a comment that I made to another poster who made a very similar statement:
I hate big pharma probably more than any other big ______. There's no money in cures, only treatment, and they milk that philosophy for all it's worth.
Anyway, OP, if it heals you, who cares?![]()
That's not really true. I'm not a big fan of a lot of stuff that pharmaceutical companies do (particularly their marketing and IP strategies), but they have a significant incentive to cure, rather than treat.
Let's say Merck has created a treatment for cancer. You would never get rid of it, and you'd have to take the medicine for the rest of your life, but you wouldn't die and you'd have a decent quality of life.
It's 5 years later, and Glaxo is looking at developing either a cure for cancer or a treatment similar to the above. If they develop the treatment, they'll be in direct competition with Merck's product. By the time they finish it, the patent on Merck's treatment will be only about 5 years from running out, at which point it will hit generics. That means that there's a very small window in which Glaxo can recoup its losses going up against an established product.
By comparison, if they make the cure, they completely out-compete Merck's product. Everyone with cancer will buy it, and they'll still get 10 years or more of use before others can make it. The cure is suddenly a much more attractive research option.
Now this is all contingent on having a competitive market which may become increasingly at risk with the huge number of mergers in the pipeline. Most of that, though is due to a coming contraction in the pharma industry, as all of their patents are running out and they're not replacing them with new medications. They are desperate for new treatments, and if there were an easy cure for cancer they'd pounce all over it.
